A randomised trial of dolutegravir (DTG)-based antiretroviral therapy vs standard of care (SOC) in children with HIV infection starting first-line or switching to second-line ART

Trial Profile

A randomised trial of dolutegravir (DTG)-based antiretroviral therapy vs standard of care (SOC) in children with HIV infection starting first-line or switching to second-line ART

Not yet recruiting
Phase of Trial: Phase II/III

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Dolutegravir (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ODYSSEY
  • Sponsors ViiV Healthcare
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 26 Jan 2016 Planned initiation date changed from 30 Jun 2015 to 1 May 2016, according to ClinicalTrials.gov record.
    • 12 Aug 2014 Planned initiation date changed to 30 Jun 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top